文献速递小儿眼科与斜弱视

弱视与斜视:以色列年轻成人患病率趋势及危险因素分析

Amblyopia and strabismus: trends in prevalence and risk factors among young adults in Israel.
PubMed 文献 · Br J Ophthalmol · 2017-08-16

该横断面研究纳入107 608名17.4±0.6岁以色列预入伍青年(1971–1994年出生),分析弱视、现患斜视及弱视危险因素的患病率趋势。结果显示单眼弱视患病率从1.2%降至0.8%(下降33%),现患斜视从1.2%降至0.6%(下降50%),而双眼弱视、斜视性弱视及重度弱视患病率保持稳定。

要点

  • 单眼弱视患病率在24个出生年份间从1.2%降至0.8%(R²=0.87,p<0.001)。
  • 现患斜视患病率从1.2%降至0.6%(R²=0.75,p<0.001)。
  • 双眼弱视(0.2%,p=0.12)、斜视性弱视及重度弱视患病率保持稳定。

核心结论

  • 年轻成人中单眼弱视和现患斜视患病率在一代人的时间内显著下降,而斜视性、双眼性或重度(单眼及双眼)弱视患病率保持稳定。
  • 作者认为国家儿童筛查项目的建立及弱视和斜视治疗效果的改善与这些趋势相吻合,因此这些早期干预可能改变了疾病的「自然史」及其在青春期的患病率。

研究设计与样本

  • 横断面研究,纳入107 608名年龄17.4±0.6岁、出生于1971年至1994年的预入伍青年。
  • 分析各出生年份间弱视、斜视、弱视严重程度及弱视危险因素(斜视、屈光参差、等视屈光不正)的患病率趋势。

主要发现

  • 单眼弱视患病率从1.2%降至0.6%(R²=0.93,p<0.001),双眼弱视患病率保持稳定于0.2%(p=0.12)。
  • 弱视总体患病率从1.2%降至0.8%(下降33%,R²=0.87,p<0.001),下降见于轻度和中度弱视,重度弱视未见下降。
  • 单眼弱视者中斜视检出率为6-12%,屈光参差检出率为11-20%,均无显著趋势;双眼弱视者中等视屈光不正检出率为46-59%,无显著趋势。
  • 研究人群斜视患病率从1.2%降至0.6%(下降50%,R²=0.75,p<0.001)。
  • 现患斜视者中轻度单眼弱视患病率增加,而中度或重度单眼弱视患病率保持相对稳定。

关键数值与推荐

  • 单眼弱视定义为任一眼最佳矫正视力(BCVA)<0.67(6/9)或双眼视力相差两行及以上。
  • 双眼弱视定义为双眼BCVA<0.67(6/9)。
  • 弱视严重程度分类:轻度(BCVA≥0.5 [6/12])、中度(BCVA<0.5 [6/12]且≥0.25 [6/24])、重度(BCVA<0.25 [6/24])。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To estimate the prevalence of amblyopia, present strabismus and amblyopia risk factors (ARFs) among young adults in Israel and to analyse trends over time of prevalence rates. METHODS: We conducted a cross-sectional study including 107 608 pre-enlistees aged 17.4±0.6 years born between 1971 and 1994. Across the birth years, the following trends of prevalence rates among young adults were analysed: prevalence of amblyopia, prevalence of strabismus, severity of amblyopia and prevalence of ARFs (strabismsus, anisometropia and isoametropia). Unilateral amblyopia was defined as best corrected visual acuity (BCVA) of <0.67 (6/9) in either eye or as an interocular difference of two lines or more. Bilateral amblyopia was defined as BCVA of <0.67 (6/9) in both eyes. The severity of amblyopia was classified as mild (BCVA ≥0.5 [6/12]), moderate (BCVA <0.5 [6/12] and ≥0.25 [6/24]) or severe (BCVA <0.25 [6/24]). RESULTS: The prevalence of young adulthood amblyopia declined by 33%, from 1.2% to 0.8% (R2=0.87, p<0.001) across 24 birth years. This decline may be due to a drop in unilateral amblyopia from 1% to 0.6% (R2=0.93, p<0.001), while the prevalence of bilateral amblyopia remained stable (0.2%, p=0.12). The decline in amblyopia was apparent in mild and moderate amblyopia, but not in severe amblyopia. Strabismus and anisometropia were detected in 6-12% and 11-20% of subjects with unilateral amblyopia, respectively, without significant trends. Strabismic amblyopia remained constant in the entire population across years. Isoametropia was detected in 46-59% of subjects with bilateral amblyopia without a significant trend across birth years. Prevalence of strabismus in the study population decreased by 50%, from 1.2% to 0.6% (R2=0.75, p<0.001). In subjects with present strabismus, the prevalence of mild unilateral amblyopia increased, while moderate or severe unilateral amblyopia remained relatively stable. CONCLUSION: Among young adults, the prevalence of unilateral amblyopia, as well as the prevalence of present strabismus, decreased significantly over a period of a generation. The prevalence of strabismic, bilateral or severe (both unilateral and bilateral) amblyopia remained stable. The establishment of the national screening programme for children and the improved utility of treatment for amblyopia and strabismus coincide with these trends. Thus, it is possible that these early interventions resulted in modification of the 'natural history' of these conditions and their prevalence in adolescence.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Shapira Y, Machluf Y, Mimouni M, et al. Amblyopia and strabismus: trends in prevalence and risk factors among young adults in Israel. Br J Ophthalmol. 2017. PMID: 28814414. doi:10.1136/bjophthalmol-2017-310364

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。